ZEALAND PHARMA A S's ticker is ZEAL and the CUSIP is 98920Y304. A total of 11 filers reported holding ZEALAND PHARMA A S in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $476,000 | +27.6% | 22,108 | +0.9% | 0.00% | 0.0% |
| Q1 2019 | $373,000 | +46.9% | 21,903 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $254,000 | -34.5% | 21,903 | -6.8% | 0.00% | 0.0% |
| Q3 2018 | $388,000 | +28.1% | 23,503 | -1.5% | 0.00% | 0.0% |
| Q2 2018 | $303,000 | -17.7% | 23,868 | -2.6% | 0.00% | 0.0% |
| Q1 2018 | $368,000 | +10.5% | 24,500 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $333,000 | -29.1% | 24,500 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $470,000 | – | 24,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT LLC | 500,000 | $17,500,000 | 0.14% |
| AWM Investment Company, Inc. | 19,981 | $699,000 | 0.12% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 5,653 | $187,000 | 0.06% |
| WELLINGTON MANAGEMENT GROUP LLP | 1,103,980 | $38,640,000 | 0.01% |
| ROYCE & ASSOCIATES LP | 10,000 | $350,000 | 0.00% |
| Winslow, Evans & Crocker, Inc. | 235 | $8,000 | 0.00% |
| Rockefeller Capital Management L.P. | 4,994 | $175,000 | 0.00% |
| JANE STREET GROUP, LLC | 36,331 | $1,272,000 | 0.00% |
| Renaissance Technologies | 26,000 | $910,000 | 0.00% |
| US BANCORP \DE\ | 260 | $9,000 | 0.00% |